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Letter by Halcox Regarding Article, “OMEGA, A
Randomized, Placebo-Controlled Trial to Test the
Effect of Highly Purified Omega-3 Fatty Acids on
Top of Modern Guideline-Adjusted Therapy After
Myocardial Infarction”
To the Editor:
I read with interest the results of the OMEGA trial,1 in which the
addition of omega-3 polyunsaturated fatty acid (PUFA) ethyl esters
to modern, evidence-based treatment of patients who had had a
recent myocardial infarction (MI) did not significantly reduce the
primary end point of sudden cardiac death (SCD) or other clinical
events within 1 year. As would be expected in a trial of contempo-
rary therapy, 78% of OMEGA trial patients underwent coronary
revascularization, and 94% received a statin on discharge, in contrast
to 5% who underwent coronary revascularization and 29% who
received lipid-lowering drugs even after 6 months in the earlier
GISSI-P trial.2 An appropriately designed trial of omega-3 PUFAs in
the context of modern management of post-MI patients is therefore
highly desirable.
The absence of significant benefits from omega-3 PUFAs might
be explained in part by the OMEGA study design. Sample size was
calculated by the use of available MI registry and clinical trial data,
the anticipated risk profile of the patients to be enrolled, and with the
expectation of a 45% reduction after 1 year in the relative risk of
SCD with omega-3 PUFA treatment as seen in GISSI-P. Thus,
1-year SCD rates of 3.5% in the control group and 1.9% in the
treated group were predicted. It is significant that the SCD rate in the
OMEGA study cohort was 50% lower than anticipated: 1.5% at 1
year in both the placebo and treatment groups. This presumably
resulted from modern treatment practices and, as acknowledged,
the possible contribution of the lower than anticipated risk profile of
the trial population. Consequently, OMEGA was underpowered
for the primary end point. Considering the ongoing improvements in
acute treatment and secondary prevention since the GISSI-P trial, it
may have been reasonable to assume lower rates for overall
mortality, the proportion of deaths resulting from SCD, or the
relative risk reduction for SCD achieved with active therapy.
Although the investigators stated it was not feasible to adopt an
event-driven protocol or to enroll the number of patients (20 000
rather than 4000) necessary to achieve statistical power with the
lower event rates observed, it should be acknowledged that firm
conclusions cannot be drawn from this underpowered study.
In addition, the 1-year duration of the OMEGA trial aimed to
investigate the early benefits of omega-3 PUFAs shown by a post
hoc time-course analysis of the first year of treatment in the GISSI-P
trial.3 However, more recent trials, such as the GISSI-HF4 and
JELIS5 trials, have shown ongoing benefits of omega-3 PUFAs when
taken for 3 years. Thus, a longer follow-up period could have
increased the power of the OMEGA trial and may also have revealed
longer-term benefits of highly purified omega-3 PUFAs post-MI.
In light of these important limitations and the consequent diffi-
culty in drawing confident conclusions, changes to current practice
in the use of highly purified omega-3 PUFAs for post-MI patients
cannot be justified on the basis of the OMEGA trial data. Adequately
powered studies are mandatory to elucidate the efficacy and tolera-
bility of high-dose omega-3 PUFAs when given alongside modern
evidence-based therapies post-MI.
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